The protein design revolution

From detecting fentanyl to blocking the virus that causes COVID-19, our scientists are pushing the limits of what proteins can do to help meet the challenges of the modern world.

Ultrapotent Vaccines

In 2019 we designed our first fully synthetic nanoparticle vaccine targeting the respiratory virus RSV, a particularly lethal virus for infants and the elderly.  This and other vaccine candidates are now being developed by Icosavax, an IPD spinout. 

In 2020 we used this same platform technology to create ultrapotent COVID-19 vaccines that in animal testing elicit neutralizing antibodies at levels more than ten times greater than the antigen from authorized mRNA vaccines. Human clinical trials are now underway.

The Dream Vaccine | Science

Cancer Immunotherapy

In 2019 we created compact proteins that stimulate the same receptors as IL-2, a powerful immunotherapeutic drug, while avoiding unwanted off-target receptor interactions. These synthetic proteins shrink tumors in mice and may become the basis for a safer type of cancer therapy. 

This technology is now being developed by our spinout company Neoleukin Therapeutics.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rapid Antivirals

In 2011 we designed proteins that target the influenza virus. These durable antivirals protect rodents from exposure to lethal amounts of the virus and can be used as diagnostic reagents in low-cost diagnostic test strips, providing improved performance as an influenza assay compared to a traditional antibody-based capture system.

We used this same technology to create potent antivirals for the COVID-19 virus and have adapted these new proteins into sensitive biosensors.

Antibodies Good. Machine-Made Molecules Better? | New York Times

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

New Nanomaterials

Our researchers are inventing new ways to pattern matter at the nanoscale. Drawing inspiration from natural protein materials such as wool, silk, and even bone, we seek to create a new generation of biomaterials with unrivaled physical properties.

These novel materials may replace many polluting petrochemicals, or give rise to new substances with unimagined functions.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Celiac Disease

In 2011 a team of UW undergraduates working out of the IPD won the grand prize at the annual iGEM competition. They sought to develop a cure for celiac disease and used computational design to re-engineer a natural enzyme to break down gluten in the harsh acidic conditions of the stomach. 

In 2015 our team published the most advanced version of the enzyme, dubbed Kuma030, which cleaves gluten molecules at sites that are known to cause an immune reaction in those with celiac disease. The enzyme was further developed by our spinout company PvP Biologics, which has been acquired by Takeda.

It’s happening now

Click here to learn how we are harnessing the power of proteins to create the next generation of medical breakthroughs.